ARDX
HealthcareArdelyx, Inc. · Biotechnology · $2B
What is Ardelyx, Inc.?
Ardelyx, Inc. is a biopharmaceutical company focused on developing medicines for gastrointestinal and cardiorenal conditions. Headquartered in Waltham, Massachusetts, the company centers its commercial and pipeline efforts on addressing unmet needs in chronic kidney disease and related disorders.
Ardelyx discovers, develops, and commercializes targeted therapies for patients with gastrointestinal and cardiorenal diseases. Its lead asset, tenapanor, has advanced through Phase III trials for irritable bowel syndrome with constipation and for controlling elevated serum phosphorus in dialysis patients with chronic kidney disease. Beyond tenapanor, the company is advancing earlier-stage programs targeting elevated potassium and metabolic acidosis — conditions that frequently affect patients with kidney or heart disease. Ardelyx also holds regional licensing agreements with partners in Japan, China, and Canada.
Ardelyx was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Tenapanor — approved and pipeline therapy for CKD and IBS-C
- RDX013 — potassium secretagogue for hyperkalemia
- RDX020 — early-stage program targeting metabolic acidosis in CKD
- Regional licensing partnerships across Japan, China, and Canada
Is ARDX a Good Stock to Buy?
UQS Score rates ARDX as Below Average overall, reflecting meaningful pipeline promise alongside notable structural limitations.
The Growth pillar stands out as the clearest positive — Ardelyx is advancing a commercial product and a pipeline with genuine unmet-need targeting. The Risk pillar also registers as Good, suggesting the company's near-term risk profile is more manageable than many early-stage biopharma peers. Valuation is rated Attractive, which may interest investors who follow quality-adjusted pricing.
The Quality and Moat pillars both register as Weak, reflecting the challenges typical of a small-cap biopharma that is still building durable competitive advantages and consistent financial performance.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ARDX pay dividends?
No — Ardelyx, Inc. does not currently pay a dividend.
Ardelyx does not currently pay a dividend. This is common for small-cap biopharmaceutical companies at Ardelyx's stage, where available capital is directed toward clinical development, commercialization efforts, and pipeline expansion rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does ARDX report earnings?
Ardelyx reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
As a commercial-stage biopharma, Ardelyx's quarterly results are closely watched for tenapanor uptake trends and operating expense management. Revenue trajectory and cash runway are key focal points each reporting period.
For the most recent quarter's results and guidance, visit Ardelyx's investor relations page directly.
ARDX Price History
+233.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Ardelyx, Inc.?
Based on Ardelyx, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ARDX Long-term Outlook
Ardelyx's UQS Growth pillar rating of Good reflects a company with a commercially launched product and a pipeline addressing chronic, high-prevalence conditions. The Attractive Valuation label suggests the market may not yet be fully pricing in the potential of the tenapanor franchise and adjacent programs. However, the Weak Quality and Moat ratings serve as a reminder that execution risk remains elevated — converting pipeline and early commercial traction into durable financial strength is the central challenge ahead.
Growth drivers
- Continued tenapanor adoption in the dialysis and IBS-C patient populations
- Pipeline progression of RDX013 and RDX020 in high-unmet-need cardiorenal indications
- Royalty and milestone potential from regional licensing partners in Japan, China, and Canada
Key risks
- Weak Quality and Moat ratings signal limited financial durability if commercial ramp slows
- Small-cap biopharma dependence on capital markets for ongoing funding
- Competitive pressure in CKD and gastrointestinal therapeutic areas from larger, better-resourced players
ARDX vs Peers
Ardelyx operates in a competitive biopharma landscape alongside other small-cap specialty companies pursuing niche therapeutic areas.
Immunocore focuses on T-cell receptor therapies for oncology and infectious disease, occupying a distinct therapeutic niche from Ardelyx's cardiorenal and GI focus.
Capricor pursues cell and exosome-based therapies for rare diseases, representing a different modality and disease focus compared to Ardelyx's small-molecule pipeline.
Oculis targets ophthalmic diseases with topical and systemic therapies, differentiating itself from Ardelyx through its exclusive focus on eye conditions.
Frequently Asked Questions
What does Ardelyx do?
Ardelyx is a biopharmaceutical company that develops medicines for gastrointestinal and cardiorenal diseases. Its lead product, tenapanor, targets irritable bowel syndrome with constipation and elevated phosphorus in dialysis patients with chronic kidney disease. The company also has earlier-stage programs addressing elevated potassium and metabolic acidosis.
Does ARDX pay dividends?
Ardelyx does not currently pay a dividend. The company reinvests its resources into clinical development and commercialization activities, which is typical for small-cap biopharmaceutical companies at this stage of growth.
When does ARDX report earnings?
Ardelyx reports financial results on a quarterly basis, in line with standard US-listed company practice. For the exact timing of upcoming earnings releases, check Ardelyx's investor relations page for the most current schedule.
Is ARDX a good stock to buy?
UQS Score rates ARDX as Below Average overall. The Growth and Risk pillars are rated Good, and Valuation is Attractive — but the Weak Quality and Moat ratings reflect real structural challenges. Whether ARDX fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is ARDX overvalued?
The UQS Valuation pillar for ARDX is rated Attractive, suggesting the stock may be reasonably priced relative to its fundamentals when compared to sector peers. However, Attractive valuation alone does not eliminate the risks associated with the company's Weak Quality and Moat ratings.
How does ARDX compare to its competitors?
Ardelyx competes in the small-cap biopharma space alongside companies like Immunocore, Capricor Therapeutics, and Oculis. Each pursues different therapeutic areas and modalities. Ardelyx's cardiorenal and GI focus, combined with a commercially launched product, distinguishes it from peers that remain entirely pre-commercial.
What is ARDX's market cap bracket?
Ardelyx is classified as a small-cap company. This means it carries the growth potential and volatility profile typical of smaller biopharmaceutical firms, including greater sensitivity to clinical and commercial execution outcomes than large-cap peers.
Who founded Ardelyx?
Ardelyx was originally incorporated under the name Nteryx, Inc. and changed its name to Ardelyx in June 2008. The company was incorporated in 2007. For detailed founding history and leadership background, Ardelyx's investor relations and corporate overview pages are the most reliable sources.
Is ARDX a long-term quality indicator?
From a long-term quality perspective, ARDX's UQS profile presents a mixed picture. The Good Growth and Risk ratings suggest near-term potential, while the Weak Quality and Moat ratings indicate the company has not yet built the durable competitive advantages typically associated with long-term compounders. Monitoring pillar progression over time is worthwhile.
What is the main competitive advantage of Ardelyx?
Ardelyx's primary differentiation lies in its targeted approach to cardiorenal and gastrointestinal biology, particularly through the mechanism behind tenapanor. Regional licensing agreements with partners in Japan, China, and Canada also extend its commercial reach without requiring full direct investment in those markets.
Is ARDX a growth stock or value stock?
Based on UQS pillar labels, ARDX leans toward growth — the Growth pillar is rated Good and Valuation is Attractive, a combination that may appeal to investors seeking pipeline-driven upside at a reasonable entry point. It does not fit the profile of a traditional value stock given its biopharma development stage.
Unlock Full ARDX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare ARDX against sector peers by pillar
- ✓Track Quality, Moat, and Growth changes over time
- ✓Get the full analyst view available to Pro members
Pro Analysis
ARDX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 48.3 | 16.7 | 21.0 | 78.8 | 67.1 | 87.0 | +0.2 |
| May 22, 2026 | 48.1 | 16.7 | 21.0 | 78.8 | 67.1 | 85.4 | 0.0 |
| May 21, 2026 | 48.1 | 16.7 | 21.0 | 78.8 | 67.1 | 85.9 | -0.2 |
| May 20, 2026 | 48.3 | 16.7 | 21.0 | 78.8 | 67.1 | 87.2 | 0.0 |
| May 19, 2026 | 48.3 | 16.7 | 21.0 | 78.8 | 67.1 | 87.0 | +0.1 |
| May 16, 2026 | 48.2 | 16.7 | 21.0 | 78.8 | 67.1 | 86.2 | +0.2 |
| May 15, 2026 | 48.0 | 16.7 | 21.0 | 78.8 | 67.1 | 84.8 | 0.0 |
| May 14, 2026 | 48.0 | 16.7 | 21.0 | 78.8 | 67.1 | 85.3 | +0.2 |
| May 12, 2026 | 47.8 | 16.7 | 21.0 | 78.8 | 67.1 | 83.9 | +0.1 |
| May 11, 2026 | 47.7 | 16.7 | 21.0 | 78.8 | 67.1 | 82.9 | +4.2 |
ARDX — Pillar Breakdown
Quality
— 16.7/100 (25%)Ardelyx, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 78.8/100 (20%)Ardelyx, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 67.1/100 (15%)Ardelyx, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 87.0/100 (15%)Ardelyx, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 21/100 (25%)Ardelyx, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ARDX.
Score Composition
Financial Data
More Stock Analysis
How is the ARDX UQS Score Calculated?
The UQS (Unified Quality Score) for Ardelyx, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Ardelyx, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Ardelyx, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.